NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

甲狀腺疾病的全球市場:2020-2027年

Global Thyroid Gland Disorders Therapeutics Market - 2020-2027

出版商 DataM Intelligence 商品編碼 965966
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
甲狀腺疾病的全球市場:2020-2027年 Global Thyroid Gland Disorders Therapeutics Market - 2020-2027
出版日期: 按訂單生產內容資訊: 英文
簡介

全球甲狀腺疾病治療藥市場成長,主要由於碘缺乏症人口增加的負擔而受到推動。碘缺乏症,原因主要是飲食中碘的攝取數量少。碘缺乏症,不僅在歐洲各國,在亞太地區及非洲的低中所得國也普遍增加。根據National Institutes of Health (NIH) ,碘缺乏症的盛行率,在更許多罹患甲狀腺疾病病的美國和墨西哥的山岳地帶變高。

本報告提供全球甲狀腺疾病治療市場相關調查,市場概要,各市場區隔及各地區的市場規模的預測,主要企業的簡介,競爭情形分析等系統性資訊。

目錄

第1章 全球甲狀腺疾病治療市場:調查手法、調查範圍

  • 調查手法
  • 調查目的、調查範圍

第2章 全球甲狀腺疾病治療市場:市場定義、概要

第3章 全球甲狀腺疾病治療市場:摘要整理

  • 市場明細:各疾病類型
  • 市場明細:各類藥物
  • 市場明細:各給藥途徑
  • 市場明細:各流通管道
  • 市場明細:各地區

第4章 全球甲狀腺疾病治療市場:市場動態

  • 市場影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球甲狀腺疾病治療市場:產業分析

  • 波特的五力分析
  • 開發平台分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 醫療費償付分析
  • 未滿足需求

第6章 全球甲狀腺疾病治療市場:COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19以前的市場情況
    • 目前市場情況
    • COVID-19以後或未來情況
  • Covid-19的價格動態
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球甲狀腺疾病治療市場:各疾病類型

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析(%):各疾病類型市場區隔
  • 市場魅力指數:各疾病類型市場區隔
    • 甲狀腺機能低下症
    • 甲狀腺功能亢進症
    • 其他

第8章 全球甲狀腺疾病治療市場:各類藥物

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析(%):各類藥物
  • 市場魅力指數:各類藥物
    • 硫脲衍生物
    • β腎上腺素阻斷劑
    • 甲狀腺荷爾蒙
    • 電解質
    • 皮質類固醇
    • 三環抗憂鬱藥物
    • 抗癲癇藥

第9章 全球甲狀腺疾病治療市場:各給藥途徑

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析(%):各給藥途徑
  • 市場魅力指數:各給藥途徑
    • 口服
    • 非口服
    • 其他

第10章 全球甲狀腺疾病治療市場:各流通管道

  • 簡介
  • 市場規模分析及與前一年同期比較成長分析(%):各流通管道
  • 市場魅力指數:各流通管道
    • 零售店
    • 線上藥局
    • 批發流通
    • 其他

第11章 全球甲狀腺疾病治療市場:各地區

  • 簡介
  • 市場規模分析、與前一年同期比較成長率分析:各地區
  • 市場魅力指數:各地區
  • 北美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長率分析:各疾病類型
    • 市場規模分析、與前一年同期比較成長率分析:各類藥物
    • 市場規模分析、與前一年同期比較成長率分析:各給藥途徑
    • 市場規模分析、與前一年同期比較成長率分析:各流通管道
    • 市場規模分析、與前一年同期比較成長率分析:各國
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長率分析:各疾病類型
    • 市場規模分析、與前一年同期比較成長率分析:各類藥物
    • 市場規模分析、與前一年同期比較成長率分析:各給藥途徑
    • 市場規模分析、與前一年同期比較成長率分析:各流通管道
    • 市場規模分析、與前一年同期比較成長率分析:各國
  • 南美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長率分析:各疾病類型
    • 市場規模分析、與前一年同期比較成長率分析:各類藥物
    • 市場規模分析、與前一年同期比較成長率分析:各給藥途徑
    • 市場規模分析、與前一年同期比較成長率分析:各流通管道
    • 市場規模分析、與前一年同期比較成長率分析:各國
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長率分析:各疾病類型
    • 市場規模分析、與前一年同期比較成長率分析:各類藥物
    • 市場規模分析、與前一年同期比較成長率分析:各給藥途徑
    • 市場規模分析、與前一年同期比較成長率分析:各流通管道
    • 市場規模分析、與前一年同期比較成長率分析:各國
  • 中東、非洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長率分析:各疾病類型
    • 市場規模分析、與前一年同期比較成長率分析:各類藥物
    • 市場規模分析、與前一年同期比較成長率分析:各給藥途徑
    • 市場規模分析、與前一年同期比較成長率分析:各流通管道
    • 市場規模分析、與前一年同期比較成長率分析:各國

第12章 全球甲狀腺疾病治療市場:競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 合併和收購分析

第13章 全球甲狀腺疾病治療市場:企業簡介

  • GlaxoSmithKline PLC
    • 企業概要
    • 產品系列、說明
    • 主要的焦點
    • 財務概要
  • Abbvie Inc.
  • Amgen Inc.
  • Novartis AG
  • Mylan NV
  • Merck KGaA
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Elexis Inc.
  • IBSA Pharma (IBSA Group)

第14章 全球甲狀腺疾病治療市場:重要考察

第15章 全球甲狀腺疾病治療市場:DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式
目錄

Market Overview

The global thyroid gland disorders therapeutics market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Thyroid gland-related disorders are caused due to the inefficiency of the thyroid gland to produce enough thyroid hormones. Thyroid disorders are mainly caused due to a deficiency of iodine in the body. Thyroid disease is most common in adults aged 30-50 years, but all age groups are affected. Cretinism and neonatal myxedema manifest in the intrauterine/perinatal period. Thyroid medications encompass an array of different options, which differ not only in their composition but their intent. Hormone replacement therapy, such as Synthroid (levothyroxine), is the most widely used drug for hypothyroidism. An anti-thyroid drug such as Tapazole (methimazole) are used for hyperthyroidism, and thyroid cancer patients may require or radioactive-iodine therapy or chemotherapy.

Market Dynamics

Rising burden of the population with iodine deficiency is driving the market growth

The global thyroid gland disorders therapeutics market growth is primarily driven by the rising burden of the population with iodine deficiency. Iodine deficiency is majorly caused by low intake of iodine in the diet. According to the World Health Organization (WHO), it is recommended that the daily intake (RDI) of iodine should be around 150 mcg per day, which is sufficient for more than 95% of all healthy adults, with pregnant and lactating women needing more. Iodine deficiency is growing commonly in the European countries, as well as in the low- and middle-income countries in Asia-Pacific and Africa. As per the National Institute of Health, the prevalence of iodine deficiency is higher in the mountainous regions of the United States and Mexico, where more number of people are falling prey to thyroid diseases.

Epidemiology

In the United States, thyroid disease is common in adults. According to a survey, the prevalence of hypothyroidism to be 1.4% in adult females and 0.1% in adult males. The prevalence of Graves disease, a hyperthyroid condition, is 1.9% in females and about 0.19% in males. Peak age incidence is in the range of 30-50 years. The congenital disease occurs in 1 per 4000 neonates in North America and Western Europe. This is seen more frequently in areas of iodine deficiency.

Globally, about 1 billion people are at risk for iodine deficiency disorders. Endemic goiter is most common manifestation and has a varying prevalence. In communities with severe iodine deficiency, prevalence is 5-15% but can reach 100%. This situation occurs in developing countries.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global thyroid gland disorders therapeutics market has slowed down from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Segment Analysis

The global thyroid gland disorders therapeutics market is segmented on the basis of disease type, drug class, route of administration, and distribution channel.

By Disease type, Hyperthyroidism is expected to witness rapid growth

Hyperthyroidism is a disorder in which the thyroid gland produces thyroxin in the large amount. According to the National Institute of Health, the prevalence of the hyperthyroidism is expected to be around 1-1.3%, and it increases up to 4-5% in older women.

Also, the disease is more commonly occurs in smokers. As smoking is rising among the general population globally, an increasing number of people are falling prey to the disease. In addition, the awareness towards the hyperthyroidism is growing in developing countries, such as India, which is expected to drive the growth of the market.

The treatment of hyperthyroidism is generally more complex than hypothyroidism, requiring one or more treatments such as Anti-thyroid drug, Radioactive iodine (RAI), Surgery to remove the gland (thyroidectomy). The only medications for hyperthyroidism are anti-thyroid drugs. Tapazole (methimazole, or MMI) and Propylthiouracil (PTU) are currently two approved for use in treating hyperthyroidism in the United States.

In December 2019, Life science company Bioiberica has launched a natural thyroid active pharmaceutical ingredient (API) for the treatment of hypothyroidism.

Thyroid hormones segment is expected to account for the largest market share during the forecast period

  • Thyroid hormones: These agents are used in thyroid hormone replacement.

Levothyroxine (Synthroid, Levoxyl): Levothyroxine is synthetic, but it is identical to natural T4; in its active form, levothyroxine influences the growth and maturation of tissues; it is involved in normal growth, metabolism, and development.

Liothyronine (Cytomel, Triostat): Liothyronine is a synthetic form of T3 (triiodothyronine). Brand names of liothyronine in the United States are Cytomel and Triostat. Due to the fact that experts, for the most part, recommend T4-monotherapy and not combination T4/T3 therapy for treating hypothyroidism, this medication is not commonly prescribed.

  • Thiourea derivatives: These medications are preferred for suppressing thyroid function.

Propylthiouracil (PTU): Propylthiouracil is a derivative of thiourea that inhibits organification of iodine by the thyroid gland. It also inhibits the conversion of T4 to T3, which is advantage over other agents.

Methimazole (Tapazole): Methimazole suppresses thyroid function and has a mechanism similar to that of PTU; it does not inhibit peripheral conversion of T4 to T3. Methimazole is fifteen times as potent as PTU. PTU-equivalent dosing can be used, divided thrice daily.

  • Beta-adrenergic blocking agents: These agents are used to treat symptomatic hyperthyroidism.

Propranolol (Inderal): This nonselective, beta-adrenergic blocking agent treats symptomatic tachycardia. Propranolol has membrane-stabilizing activity and decreases the automaticity of contractions.

  • Electrolytes: These agents replace depleted electrolytes.

Potassium chloride (K-DUR): Potassium chloride is essential for the transmission of nerve impulses, maintenance of intracellular tonicity, and maintenance of normal renal function. It is also vital for skeletal and smooth muscles. Potassium chloride replaces potassium lost in thyrotoxic periodic paralysis.

Corticosteroids: These agents provide immunosuppressive therapy for Graves ophthalmopathy, especially in cases of severe exophthalmos.

Prednisone (Deltasone, Sterapred, Orasone): Prednisone is a widely used glucocorticoid that suppresses inflammatory processes by reversing increased capillary permeability and suppressing PMN activity; it is used to treat allergic, inflammatory, and autoimmune disorders.

Tricyclic antidepressants: These agents may help relieve painful polyneuropathy.

Amitriptyline (Elavil): By inhibiting the reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, amitriptyline may increase the synaptic concentration of these neurotransmitters in the CNS; it is useful as an analgesic for certain chronic and neuropathic pain.

  • Antiepileptic agents: These agents are useful in treating neuropathic pain.

Gabapentin (Neurontin): Gabapentin's exact mechanism is unknown. It is structurally related to GABA and is useful in some pain syndromes

Geographical Analysis

North America region holds the largest market share in global Thyroid Gland Disorders Therapeutics market

North America region is dominating the global thyroid gland disorders therapeutics market accounted for the largest market share in 2019, owing to the high prevalence rate for thyroid disorders in the United States, rising risk factors such as obesity and diabetes, and well-established healthcare infrastructure.

In North America, around 35 million people suffer from at least one form of thyroid disease. As per the American Association of Clinical Endocrinologists (AACE) survey, around 13 million people or 4.80% of the population, had thyroid disorders in the United States in 2016. Also, as per the American Thyroid Association, in 2017, around 4.6% of the US population had hypothyroidism, and 1.3% had hyperthyroidism.

Various companies have collaborated with the America Thyroid Association (ATA), as the association has supported various research grants worth about US$ 2.2 million. Several large players are involved in raising awareness in American society through campaigns towards thyroid disorders. For instance, in 2017 and 2018, Merck launched "It is not you. It is your thyroid" campaign. The awareness campaign is in collaboration with the Thyroid Federation International (TFI), as it is observed by companies that the thyroid disorders are underdiagnosed.

In January 2020, The American Association of Clinical Endocrinologists launched the Up To Here campaign to raise awareness of thyroid diseases and to help U.S. residents recognize symptoms, risk factors and the need to seek treatment. The campaign, launched to coincide with Thyroid Awareness Month, is designed to highlight common symptoms associated with thyroid disease, such as weight gain and mood or sleep disorders.

Asia-Pacific region is growing at the fastest CAGR during the forecast period.

The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period, due to the rising demand for thyroid treatments in developing countries such as China, India, and South Korea. These countries are emerging as major destinations for outsourcing clinical trials, drug manufacturing, and pathology testing. The development of effective drug therapies for thyroid disorders and rise in the number of disease awareness programs in developing countries are responsible for the market growth in this region.

Competitive Landscape

The thyroid gland disorders therapeutics market is moderately competitive and majorly consists of the global players. The rising drug development may witness the entry of few small- or mid-sized companies in the market during the forecast period. Some of the key players which are contributing to the growth of the market include Abbvie Inc., GlaxoSmithKline PLC, Amgen Inc., Novartis AG, Mylan NV, Merck KGaA, Pfizer Inc., Takeda Pharmaceutical Company Limited, among others.

Pfizer Inc.

Overview:

Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.

Product Portfolio:

  • LEVOXYL® (levothyroxine sodium) : LEVOXYL is L-thyroxine (T4) indicated in pediatric and adult patients for :

Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer

  • CYTOMEL® (liothyronine sodium): CYTOMEL is an L-triiodothyronine (T3) indicated for:

Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer .

Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy

Key Development:

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the thyroid gland disorders therapeutics gobally. For instance,

  • In January 2020, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis).
  • In March 2018, Eisai Co., Ltd., and Merck, known as MSD outside the US and Canada, announced that the companies a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.
  • In October 2017, Abbott acquired Alere Inc., a diagnostic device and service provider organization that manufactures diagnostic screening device, ThyroTest used for initial detection of hypothyroidism.
  • In November 2015, AbbVie introduced Good Morning Hypothyroidism (GMH), an all-inclusive program that focuses on a daily routine for managing the life-long condition of hypothyroidism.

Why Purchase the Report?

  • Visualize the composition of the thyroid gland disorders therapeutics market segmentation by disease type, drug class, route of administration, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in thyroid gland disorders therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of thyroid gland disorders therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global thyroid gland disorders therapeutics market report would provide an access to an approx. 69 market data table, 66 figures and 300 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Thyroid Gland Disorders Therapeutics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Thyroid Gland Disorders Therapeutics Market - Market Definition and Overview

3. Global Thyroid Gland Disorders Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Drug Class
  • 3.3. Market Snippet by Route of Administration
  • 3.4. Market Snippet by Distribution Channel
  • 3.5. Market Snippet by Region

4. Global Thyroid Gland Disorders Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing patient population with iodine deficiency
      • 4.1.1.2. Rising government initiatives for thyroid gland screening and treatment
      • 4.1.1.3. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Alternative herbal and acupuncture therapies
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Thyroid Gland Disorders Therapeutics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Thyroid Gland Disorders Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Thyroid Gland Disorders Therapeutics Market - By Disease Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
  • 7.3. Market Attractiveness Index, By Disease Type Segment
    • 7.3.1. Hypothyroidism*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Hyperthyroidism
    • 7.3.3. Others

8. Global Thyroid Gland Disorders Therapeutics Market - By Drug Class

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.3. Market Attractiveness Index, By Drug Class Segment
    • 8.3.1. Thiourea derivatives*
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
      • 8.3.1.2. Propylthiouracil (PTU)
      • 8.3.1.3. Methimazole (Tapazole)
    • 8.3.2. Beta-adrenergic blocking agents
      • 8.3.2.1. Propranolol (Inderal)
      • 8.3.2.2. Others
    • 8.3.3. Thyroid hormones
      • 8.3.3.1. Levothyroxine (Synthroid, Levoxyl, Unithroid, and Tirosint)
      • 8.3.3.2. Liothyronine (Cytomel, Triostat)
      • 8.3.3.3. Others
    • 8.3.4. Electrolytes
      • 8.3.4.1. Potassium chloride (K-DUR)
      • 8.3.4.2. Others
    • 8.3.5. Corticosteroids
      • 8.3.5.1. Prednisone (Deltasone, Sterapred, Orasone)
      • 8.3.5.2. Others
    • 8.3.6. Tricyclic antidepressants
      • 8.3.6.1. Amitriptyline (Elavil)
      • 8.3.6.2. Others
    • 8.3.7. Antiepileptic agents
      • 8.3.7.1. Gabapentin (Neurontin)
      • 8.3.7.2. Others

9. Global Thyroid Gland Disorders Therapeutics Market - By Route of Administration

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3. Market Attractiveness Index, By Route of Administration Segment
    • 9.3.1. Oral*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Parenteral
    • 9.3.3. Others

10. Global Thyroid Gland Disorders Therapeutics Market - By Distribution Channel

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 10.3. Market Attractiveness Index, By Distribution Channel Segment
    • 10.3.1. Retail Stores*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Online Pharmacy
    • 10.3.3. Wholesale Distribution
    • 10.3.4. Others

11. Global Thyroid Gland Disorders Therapeutics Market - By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

12. Global Thyroid Gland Disorders Therapeutics Market - Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Global Thyroid Gland Disorders Therapeutics Market- Company Profiles

  • 13.1. GlaxoSmithKline PLC*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Abbvie Inc.
  • 13.3. Amgen Inc.
  • 13.4. Novartis AG
  • 13.5. Mylan NV
  • 13.6. Merck KGaA
  • 13.7. Pfizer Inc.
  • 13.8. Takeda Pharmaceutical Company Limited
  • 13.9. Elexis Inc.
  • 13.10. IBSA Pharma (IBSA Group)

LIST NOT EXHAUSTIVE

14. Global Thyroid Gland Disorders Therapeutics Market - Premium Insights

15. Global Thyroid Gland Disorders Therapeutics Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us